HomeACADEMIA
ACADEMIA

Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
(Jul.11.2018)

A leukemia specialist expressed in an interview with Jiho optimism not only about FLT3 inhibitors, which a number of drug makers are competing to develop, but about drugs with other mechanisms of action as well including smoothened (SMO) and B-cell lymphoma 2 (BCL-2) inhibitors for acute myeloid leukemia (AML) ...
(LOG IN FOR FULL STORY)

News Calendar